Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on rare disease treatments through cell and exosome-based therapeutics, has announced its participation in two upcoming investor conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, from 11:30-11:55 a.m. ET, featuring a fireside chat, industry panel, and one-on-one meetings. Additionally, Capricor will participate in the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 10:00-10:50 a.m. ET. The Piper Sandler presentation will be available via webcast on Capricor's website.
Capricor Therapeutics (NASDAQ: CAPR), un'azienda biotecnologica focalizzata sui trattamenti per malattie rare attraverso terapie a base di cellule ed esosomi, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. L'azienda presenterà alla 36ª Conferenza Annuale sulla Salute di Piper Sandler il 3 dicembre 2024, dalle 11:30 alle 11:55 a.m. ET, con un'intervista dal vivo, un panel di settore e incontri individuali. Inoltre, Capricor parteciperà al Summit di Oppenheimer sui Movimenti nelle Malattie Rare il 12 dicembre 2024, dalle 10:00 alle 10:50 a.m. ET. La presentazione di Piper Sandler sarà disponibile in streaming sul sito web di Capricor.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en tratamientos para enfermedades raras a través de terapias basadas en células y exosomas, ha anunciado su participación en dos próximas conferencias para inversores. La compañía presentará en la 36ª Conferencia Anual de Salud de Piper Sandler el 3 de diciembre de 2024, de 11:30 a 11:55 a.m. ET, que incluirá una charla informal, un panel de la industria y reuniones uno a uno. Además, Capricor participará en el Summit de Oppenheimer sobre Movimientos en Enfermedades Raras el 12 de diciembre de 2024, de 10:00 a 10:50 a.m. ET. La presentación de Piper Sandler estará disponible a través de un webcast en el sitio web de Capricor.
Capricor Therapeutics (NASDAQ: CAPR)는 세포 및 엑소좀 기반 치료를 통해 희귀 질환 치료에 중점을 두고 있는 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참석한다고 발표했습니다. 회사는 2024년 12월 3일 오전 11:30부터 11:55까지 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에서 발표를 진행하며, 여기에는 대화모임, 업계 패널 및 일대일 미팅이 포함됩니다. 또한 Capricor는 2024년 12월 12일 오전 10:00부터 10:50까지 오펜하이머 희귀 질환 서밋에 참여할 예정입니다. Piper Sandler 발표는 Capricor 웹사이트를 통해 웹캐스트로 제공될 것입니다.
Capricor Therapeutics (NASDAQ: CAPR), une société de biotechnologie axée sur les traitements des maladies rares par des thérapies basées sur des cellules et des exosomes, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise présentera lors de la 36e Conférence Annuelle de Santé de Piper Sandler le 3 décembre 2024, de 11h30 à 11h55 ET, comprenant un entretien informel, un panel de l'industrie et des réunions individuelles. De plus, Capricor participera au Sommet Oppenheimer des Acteurs dans les Maladies Rares le 12 décembre 2024, de 10h00 à 10h50 ET. La présentation de Piper Sandler sera disponible en webcast sur le site web de Capricor.
Capricor Therapeutics (NASDAQ: CAPR), ein Biotechnologieunternehmen, das sich auf die Behandlung seltener Krankheiten durch zell- und exosomenbasierte Therapien spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 3. Dezember 2024 von 11:30 bis 11:55 Uhr ET auf der 36. jährlichen Gesundheitskonferenz von Piper Sandler präsentieren, einschließlich eines Fireside Chats, eines Branchengremiums und Einzelgesprächen. Darüber hinaus wird Capricor am 12. Dezember 2024 von 10:00 bis 10:50 Uhr ET beim Oppenheimer Movers in Rare Disease Summit teilnehmen. Die Präsentation von Piper Sandler wird über einen Webcast auf der Website von Capricor verfügbar sein.
- None.
- None.
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences.
| Event: | Piper Sandler 36th Annual Healthcare Conference (New York, NY) |
| Presentation: | Tuesday, December 3, 2024 from 11:30-11:55 a.m. ET |
| Format: | Fireside chat, industry panel and one-on-one meetings |
| Webcast Link | Click here |
| Event: | Oppenheimer Movers in Rare Disease Summit (New York, NY) |
| Presentation: | Thursday, December 12, 2024 from 10:00-10:50 a.m. ET |
| Format: | Fireside chat and one-on-one meetings |
The live webcast of the Piper Sandler fireside chat can be accessed on the “News & Events” page in the Investor section of Capricor’s website at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on November 14, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
When is Capricor Therapeutics (CAPR) presenting at the Piper Sandler Healthcare Conference in 2024?
What investor conferences is Capricor Therapeutics (CAPR) attending in December 2024?
Where can investors watch Capricor Therapeutics' (CAPR) Piper Sandler presentation?
What is the format of Capricor Therapeutics' (CAPR) presentations at the December 2024 conferences?
